Flag of the European Union EU Clinical Trials Register Help

Clinical trials for LEO Pharma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    170 result(s) found for: LEO Pharma. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2015-005279-25 Sponsor Protocol Number: LP0058-1072 Start Date*: 2016-06-22
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris A phase 2a proof of concept study comparing an oral tablet formulation of LEO 32731 with a corresponding placebo tablet in pati...
    Medical condition: Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000037-23 Sponsor Protocol Number: LP0084-1014 Start Date*: 2014-07-29
    Sponsor Name:LEO Pharma A/S
    Full Title: Clinical Study Protocol Safety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on full balding scalp in subjects with actinic keratosis Part 1: A pha...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000556-95 Sponsor Protocol Number: LP0053-1004 Start Date*: 2017-01-03
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 90100 twice weekly maintenance regimen for psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021941-38 Sponsor Protocol Number: LEO 90110-O21 Start Date*: 2010-12-22
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 90110 ointment in the treatment of psoriasis vulgaris
    Medical condition: psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017858-12 Sponsor Protocol Number: LEO 22811-S22 Start Date*: 2010-05-11
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 2a proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000900-40 Sponsor Protocol Number: LP0133-1273 Start Date*: 2019-01-15
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical application of delgocitinib cream 1, 3, 8, and 20 mg/g...
    Medical condition: Chronic hand eczema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10066695 Chronic hand dermatitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004961-38 Sponsor Protocol Number: EXP-2177 Start Date*: 2021-03-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria
    Medical condition: cholinergic urticaria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10008675 Cholinergic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004686-14 Sponsor Protocol Number: LP0053-1003 Start Date*: 2014-05-27
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 90100 aerosol foam compared to calcipotriol plus betamethasone dipropionate gel in subjects with psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002450-12 Sponsor Protocol Number: LP0084-1194 Start Date*: 2016-01-04
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up Part 1: 3-day treatment period including an 8-week follow-up period Part 2:...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005463-10 Sponsor Protocol Number: PLQ-001 Start Date*: 2008-02-06
    Sponsor Name:LEO Pharma A/S
    Full Title: A plaque test comparing three marketed products and two products in development and a vehicle control for the treatment of psoriasis vulgaris
    Medical condition: Psoriasis vulgaris lesions located on the arms, legs or trunk.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013792-22 Sponsor Protocol Number: LEO 29102-C21 Start Date*: Information not available in EudraCT
    Sponsor Name:LEO Pharma A/S
    Full Title: A Phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel (Pim...
    Medical condition: Diagnosis of atopic dermatitis graded as mild to moderate according to the Rajka and Langeland system.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-002720-24 Sponsor Protocol Number: EXP-1377 Start Date*: 2017-10-17
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a
    Medical condition: Alopecia Areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003615-22 Sponsor Protocol Number: EXP-1373 Start Date*: 2019-05-28
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehi...
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000404-37 Sponsor Protocol Number: LP0133-1181 Start Date*: 2021-04-14
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 1 open-label, multi-centre, single-arm trial to evaluate the safety and pharmacokinetics (including MUsT) of twice daily topical application of delgocitinib cream for 8 weeks in adults, ado...
    Medical condition: Atopic Dermatitis (AD)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006340-27 Sponsor Protocol Number: LP0133-1426 Start Date*: 2022-04-21
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adolescents 12-17 ye...
    Medical condition: Chronic Hand Eczema
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004858 10084778 Chronic hand eczema LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002452-27 Sponsor Protocol Number: LP0084-1196 Start Date*: 2015-12-28
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12-month follow-up Part 1: 3-day treatment period including an 8-week follow-up period Part 2:...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002962-15 Sponsor Protocol Number: LP0133-1403 Start Date*: 2021-08-10
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chro...
    Medical condition: Chronic Hand Eczema
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004858 10084778 Chronic hand eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Completed) FR (Completed) ES (Ongoing) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002451-10 Sponsor Protocol Number: LP0084-1195 Start Date*: 2015-12-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12-month follow-up Part 1: 3-day treatment period including an 8-week follow-up period Part 2: ...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002961-32 Sponsor Protocol Number: LP0133-1402 Start Date*: 2021-07-01
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) BE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002098-40 Sponsor Protocol Number: LP0133-1182 Start Date*: 2016-02-10
    Sponsor Name:LEO Pharma A/S
    Full Title: A Phase 2a, Proof of Concept Trial, testing twice daily application of LEO 124249 ointment 30mg/g in the treatment of mild to moderate inverse psoriasis
    Medical condition: inverse psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10063160 Inverse psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 06:43:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA